Biomarkers; Neurofilaments; NfL; Sarcopenia; Humans; Aged; Intermediate Filaments; Hand Strength/physiology; Muscle Strength; Absorptiometry, Photon/methods; Absorptiometry, Photon; Hand Strength; Aging; Geriatrics and Gerontology
Abstract :
[en] [en] BACKGROUND: As clinical tests, such as gait speed, require nervous system integrity to be performed properly, sarcopenia shares features with neurological diseases. Neurofilament light chains (NF-L) are now used as a blood-biomarker of neuronal damage, and its expression might be altered in sarcopenia. We aimed to assess NF-L concentrations in a large cohort of older individuals screened for sarcopenia.
METHODS: The SarcoPhAge cohort is a Belgian cohort of 534 community-dwelling older adults with an ongoing 10-year follow-up. Sarcopenia diagnosis was established at inclusion according to the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria. Muscle strength was evaluated with a hydraulic hand dynamometer, appendicular lean mass by Dual-Energy X-ray Absorptiometry (DXA) and physical performance by the Short Physical Performance Battery (SPPB). NF-L was measured on all available sera collected at the time of inclusion (n = 409) using SiMoA technology (Quanterix°).
RESULTS: In the multivariate model, NF-L was associated with performance tests such as gait speed (p < 0.0001) and SPPB scores (p = 0.0004). An association was also observed with muscle strength (p = 0.0123) and lean mass (p = 0.0279). In the logistic regression model, NF-L was an independent predictor of severe sarcopenia (p = 0.0338; OR = 20.0; 95% CI 1.39-287.7) with satisfactory diagnostic accuracy (AUC: 0.828) and subjects with an SPPB score ≤ 8 had higher odds of having increased NF-L (p < 0.0001; OR = 23.9; 95% CI 5.5-104).
CONCLUSIONS: These data highlight the potential for using NF-L to investigate the pathophysiology of sarcopenia severity and the neurological features associated with performance tests. However, these results need to be confirmed with other cohorts in different settings.
Disciplines :
Laboratory medicine & medical technology
Author, co-author :
Ladang, Aurélie ; Centre Hospitalier Universitaire de Liège - CHU > > Service de chimie clinique
KOVACS, Stéphanie ; Centre Hospitalier Universitaire de Liège - CHU > > Service de chimie clinique
Lengele, Laetitia ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Locquet, Médéa ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie clinique
Beaudart, Charlotte ; Centre Hospitalier Universitaire de Liège - CHU > > Service de médecine de l'appareil locomoteur
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique
Bruyère, Olivier ; Centre Hospitalier Universitaire de Liège - CHU > > Service de médecine de l'appareil locomoteur
Cavalier, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > > Service de chimie clinique
Language :
English
Title :
Neurofilament-light chains (NF-L), a biomarker of neuronal damage, is increased in patients with severe sarcopenia: results of the SarcoPhAge study.
Publication date :
October 2023
Journal title :
Aging Clinical and Experimental Research
ISSN :
1594-0667
eISSN :
1720-8319
Publisher :
Springer Science and Business Media Deutschland GmbH, Germany
Morley JE, Abbatecola AM, Argiles JM et al (2011) Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc 12:403–409. 10.1016/j.jamda.2011.04.014 DOI: 10.1016/j.jamda.2011.04.014
Beaudart C, Biver E, Reginster JY et al (2017) Validation of the SarQoL®, a specific health-related quality of life questionnaire for Sarcopenia. J Cachexia Sarcopenia Muscle 8:238–244. 10.1002/jcsm.12149 DOI: 10.1002/jcsm.12149
Schaap LA, Van Schoor NM, Lips P et al (2018) Associations of sarcopenia definitions, and their components, with the incidence of recurrent falling and fractures: the longitudinal aging study Amsterdam. J Gerontol Ser A Biol Sci Med Sci 73:1199–1204. 10.1093/gerona/glx245 DOI: 10.1093/gerona/glx245
Steffl M, Bohannon RW, Sontakova L et al (2017) Relationship between sarcopenia and physical activity in older people: a systematic review and meta-analysis. Clin Interv Aging 12:835–845. 10.2147/CIA.S132940 DOI: 10.2147/CIA.S132940
Cruz-Jentoft AJ, Bahat G, Bauer J et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48:16–31. 10.1093/ageing/afy169 DOI: 10.1093/ageing/afy169
Chen LK, Woo J, Assantachai P et al (2020) Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc 21:300-307.e2. 10.1016/j.jamda.2019.12.012 DOI: 10.1016/j.jamda.2019.12.012
Studenski SA, Peters KW, Alley DE et al (2014) The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol Ser A Biol Sci Med Sci A 69:547–558. 10.1093/gerona/glu010 DOI: 10.1093/gerona/glu010
Leong DP, Teo KK, Rangarajan S et al (2015) Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet 386:266–273. 10.1016/S0140-6736(14)62000-6 DOI: 10.1016/S0140-6736(14)62000-6
Buckinx F, Landi F, Cesari M et al (2018) Pitfalls in the measurement of muscle mass: a need for a reference standard. J Cachexia Sarcopenia Muscle 9:269–272. 10.1002/jcsm.12268 DOI: 10.1002/jcsm.12268
Guralnik JM, Ferrucci L, Pieper CF et al (2000) Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol Ser A Biol Sci Med Sci 55:M221–M231. 10.1093/gerona/55.4.M221 DOI: 10.1093/gerona/55.4.M221
Kara M, Özçakar L, Kaymak B et al (2020) A “neuromuscular look” to sarcopenia: Is it a ‘movement disorder’? J Rehabil Med 52:00042. 10.2340/16501977-2672 DOI: 10.2340/16501977-2672
Delbono O, Rodrigues ACZ, Bonilla HJ et al (2021) The emerging role of the sympathetic nervous system in skeletal muscle motor innervation and sarcopenia. Ageing Res Rev 67:101305. 10.1016/j.arr.2021.101305 DOI: 10.1016/j.arr.2021.101305
Kwon YN, Yoon SS (2017) Sarcopenia: neurological point of view. J Bone Metab 24:83–89. 10.11005/jbm.2017.24.2.83
Venturelli M, Reggiani C, Schena F (2022) Beyond the current knowledge on sarcopenia: new insight on neuromuscular factors. Aging Clin Exp Res 34:1183–1185. 10.1007/s40520-022-02082-3 DOI: 10.1007/s40520-022-02082-3
Delbono O (2003) Neural control of aging skeletal muscle. Aging Cell 2:21–29. 10.1046/j.1474-9728.2003.00011.x DOI: 10.1046/j.1474-9728.2003.00011.x
Bertschi D, Kiss CM, Beerli N et al (2022) Impact of sarcopenia on daily functioning: a cross-sectional study among older inpatients. Aging Clin Exp Res 34:2041–2046. 10.1007/s40520-022-02175-z DOI: 10.1007/s40520-022-02175-z
Hu F, Liu H, Liu X et al (2021) Nutritional status mediates the relationship between sarcopenia and cognitive impairment: findings from the WCHAT study. Aging Clin Exp Res 33:3215–3222. 10.1007/s40520-021-01883-2 DOI: 10.1007/s40520-021-01883-2
Handing EP, Leng XI, Kritchevsky SB et al (2020) Association between physical performance and cognitive function in older adults across multiple studies: a pooled analysis study. Innov Aging 4:igaa050. 10.1093/geroni/igaa050 DOI: 10.1093/geroni/igaa050
George KM, Gilsanz P, Peterson RL et al (2021) Physical performance and cognition in a diverse cohort: Kaiser Healthy Aging and Diverse Life Experiences (KHANDLE) study. Alzheimer Dis Assoc Disord 35:23–29. 10.1097/WAD.0000000000000428 DOI: 10.1097/WAD.0000000000000428
Zucchelli A, Manzoni F, Morandi A et al (2021) The association between low skeletal muscle mass and delirium: results from the nationwide multi-centre Italian Delirium Day 2017. Aging Clin Exp Res 34:349. 10.1007/s40520-021-01950-8 DOI: 10.1007/s40520-021-01950-8
Ladang A, Beaudart C, Reginster JY et al (2023) Biochemical markers of musculoskeletal health and aging to be assessed in clinical trials of drugs aiming at the treatment of sarcopenia: consensus paper from an expert group meeting organized by the european society for clinical and economic aspects of O. Calcif Tissue Int 112:197. 10.1007/s00223-022-01054-z DOI: 10.1007/s00223-022-01054-z
Lambertsen KL, Soares CB, Gaist D et al (2020) Neurofilaments: The C-reactive protein of neurology. Brain Sci 10:56. 10.3390/brainsci10010056 DOI: 10.3390/brainsci10010056
Ashton NJ, Janelidze S, Al Khleifat A et al (2021) A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun 12:3400. 10.1038/s41467-021-23620-z DOI: 10.1038/s41467-021-23620-z
Ladang A, Kovacs S, Lengelé L et al (2022) Neurofilament light chain concentration in an aging population. Aging Clin Exp Res 34:331–339. 10.1007/s40520-021-02054-z DOI: 10.1007/s40520-021-02054-z
Pratt J, De Vito G, Segurado R et al (2022) Plasma neurofilament light levels associate with muscle mass and strength in middle-aged and older adults: findings from GenoFit. J Cachexia Sarcopenia Muscle 13:1811–1820. 10.1002/jcsm.12979 DOI: 10.1002/jcsm.12979
Beaudart C, Reginster JY, Petermans J et al (2015) Quality of life and physical components linked to sarcopenia: The SarcoPhAge study. Exp Gerontol 69:103–110. 10.1016/j.exger.2015.05.003 DOI: 10.1016/j.exger.2015.05.003
Roberts HC, Denison HJ, Martin HJ et al (2011) A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing 40:1 DOI: 10.1093/ageing/afr051
Inker LA, Schmid CH, Tighiouart H et al (2012) Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367:20–29. 10.1056/nejmoa1114248 DOI: 10.1056/nejmoa1114248
Locquet M, Beaudart C, Hajaoui M et al (2019) Three-year adverse health consequences of sarcopenia in community-dwelling older adults according to 5 diagnosis definitions. J Am Med Dir Assoc 20:43-46.e2. 10.1016/j.jamda.2018.06.004 DOI: 10.1016/j.jamda.2018.06.004
He L, de Souto BP, Giudici KV et al (2021) Cross-sectional and longitudinal associations between plasma neurodegenerative biomarkers and physical performance among community-dwelling older adults. J Gerontol Ser A 76:1874–1881. 10.1093/gerona/glaa284 DOI: 10.1093/gerona/glaa284
Barro C, Chitnis T, Weiner HL (2020) Blood neurofilament light: a critical review of its application to neurologic disease. Ann Clin Transl Neurol 7:2508–2523. 10.1002/acn3.51234 DOI: 10.1002/acn3.51234
Arslan B, Zetterberg H (2023) Neurofilament light chain as neuronal injury marker—What is needed to facilitate implementation in clinical laboratory practice? Clin Chem Lab Med 61:1140–1149. 10.1515/cclm-2023-0036 DOI: 10.1515/cclm-2023-0036
Wiedmer P, Jung T, Castro JP et al (2021) Sarcopenia—molecular mechanisms and open questions. Ageing Res Rev 65:101200. 10.1016/j.arr.2020.101200 DOI: 10.1016/j.arr.2020.101200
Lu W, Giudici KV, Guyonnet S et al (2022) Associations of plasma neurofilament light chain and progranulin with frailty in older adults. J Am Geriatr Soc 70:1236–1243. 10.1111/jgs.17604 DOI: 10.1111/jgs.17604
Lu W, Vellas B, de Souto BP (2022) Reply to: Comment on: the associations of plasma neurofilament light chain and progranulin with frailty in older adults. J Am Geriatr Soc 70:2169–2170. 10.1111/jgs.17782 DOI: 10.1111/jgs.17782
Kaloostian C, Shil MB (2022) Comment on: the associations of plasma neurofilament light chain (NfL) and progranulin (PGRN) with frailty in older adults. J Am Geriatr Soc 70:2167–2168 DOI: 10.1111/jgs.17780
Yuan A, Nixon RA (2021) Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies. Front Neurosci 15:689938 DOI: 10.3389/fnins.2021.689938
Curcio F, Ferro G, Basile C et al (2016) Biomarkers in sarcopenia: a multifactorial approach. Exp Gerontol 85:1–8. 10.1016/j.exger.2016.09.007 DOI: 10.1016/j.exger.2016.09.007
Rodriguez-Mañas L, Araujo de Carvalho I, Bhasin S et al (2020) ICFSR task force perspective on biomarkers for sarcopenia and frailty. J Frailty Aging 9:4–8. 10.14283/jfa.2019.32
Kalinkovich A, Livshits G (2015) Sarcopenia—the search for emerging biomarkers. Ageing Res Rev 22:58–71. 10.1016/j.arr.2015.05.001 DOI: 10.1016/j.arr.2015.05.001
Kuhle J, Kropshofer H, Haering DA et al (2019) Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 92:e1007–e1015. 10.1212/WNL.0000000000007032 DOI: 10.1212/WNL.0000000000007032
